Steven Rosenberg (Q2347448)
Jump to navigation
Jump to search
American cancer researcher
- Steven A. Rosenberg
- Steven A Rosenberg
- S. A. Rosenberg
- S.A. Rosenberg
- S A Rosenberg
Language | Label | Description | Also known as |
---|---|---|---|
English | Steven Rosenberg |
American cancer researcher |
|
default for all languages | Steven Rosenberg |
Statements
1 reference
Steven Rosenberg (English)
0 references
2 August 1940
1 reference
9 October 2017
Steven A. Rosenberg
1 reference
1 reference
1 reference
2023
"for breakthrough research advancing chimeric antigen receptor T-cell therapy for the treatment of cancer." (English)
1 reference
23 September 2023
2024
For lifelong scientific achievements and paramount contributions to cancer research and patient care, most notably his pioneering research that established interleukin-2 (IL-2) as the first U.S. Food and Drug Administration (FDA)-approved cancer immunotherapy and his major contributions to establishing fundamental principles involving cellular and genetic engineering and immunotherapeutic development. (English)
Rosenberg, Steven A.
Identifiers
1 reference
1 reference
1 reference
1 reference
2 references
1 reference
1 reference
Sitelinks
Wikipedia(10 entries)
- arwiki ستيفن روزنبرغ
- arzwiki ستيفن روزنبرج
- dewiki Steven A. Rosenberg
- enwiki Steven Rosenberg
- fawiki استیون روزنبرگ
- hewiki סטיבן רוזנברג
- itwiki Steven Rosenberg
- jawiki スティーヴン・ローゼンバーグ
- ptwiki Steven Rosenberg
- ruwiki Розенберг, Стивен